Inventor

Ronald Vogels

Inventor

Linschoten, NL

Overview

2002–2020

Patent span

Chemistry

Primary field (CPC C)

Patents· 47 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C12Nprimary

C12NMicroorganisms or enzymes31%

A61KPreparations for medical, dental or toiletry purposes21%

C07KPeptides21%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations19%

G01NInvestigating or analysing materials by determining their chemical or physical properties6%

Y02ATechnologies for adaptation to climate change2%

H03HImpedance networks, e.g. resonant circuits1%

PatentTitleYear

10,703,804Binding molecules directed against influenza hemagglutinin and uses thereof2020 10,370,435Binding molecules directed against influenza hemagglutinin and uses thereof2019 9,969,778Influenza virus vaccines and uses thereof2018 9,593,159'Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses'2017 9,452,211'Influenza virus vaccines and uses thereof'2016 9,228,205'Complementing cell lines'2016 9,200,064'Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof'2015 9,005,621'Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof'2015 8,961,978'Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses'2015 8,852,595'Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof'2014 8,834,881'Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof'2014 8,729,973'MEMS resonator'2014 8,609,402'Multivalent vaccines comprising recombinant viral vectors'2013 8,227,243'Settings for recombinant adenoviral-based vaccines'2012 8,221,971'Serotype of adenovirus and uses thereof'2012 8,202,723'Multivalent vaccines comprising recombinant viral vectors'2012 8,114,637'Packaging cells for recombinant adenovirus'2012 8,076,131'Settings for recombinant adenoviral-based vaccines'2011 8,052,967'Stable adenoviral vectors and methods for propagation thereof'2011 8,012,467'Multivalent vaccines comprising recombinant viral vectors'2011 7,968,087'Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells'2011 7,906,113'Serotype of adenovirus and uses thereof'2011 7,820,440'Means and methods for producing adenovirus vectors'2010 7,816,104'Packaging cells for recombinant adenovirus'2010 7,749,493'Chimeric adenoviruses'2010 7,604,960'Transient protein expression methods'2009 7,598,078'Settings for recombinant adenoviral-based vaccines'2009 7,468,181'Means and methods for the production of adenovirus vectors'2008 7,344,883'Complementing cell lines'2008 7,285,265'Stable adenoviral vectors and methods for propagation thereof'2007 7,270,811'Serotype of adenovirus and uses thereof'2007 7,250,293'Complementing cell lines'2007 7,238,528'Means and methods for fibroblast-like or macrophage-like cell transduction'2007 7,037,716'Packaging systems for human recombinant adenovirus to be used in gene therapy'2006 7,029,848'High throughput screening of gene function using libraries for functional genomics applications'2006 6,974,695'Complementing cell lines'2005 6,929,946'Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells'2005 6,913,922'Serotype of adenovirus and uses thereof'2005 6,905,678'Gene delivery vectors with cell type specificity for mesenchymal stem cells'2005 6,878,549'Packaging systems for human recombinant adenovirus to be used in gene therapy'2005 6,869,794'Complementing cell lines'2005 6,869,936'Means and methods for fibroblast-like or macrophage-like cell transduction'2005 6,803,234'Gene delivery vectors with cell type specificity for primary human chondrocytes'2004 6,670,188'Packaging systems for human recombinant adenovirus to be used in gene therapy'2003 6,492,169'Complementing cell lines'2002 6,413,776'High throughput screening of gene function using adenoviral libraries for functional genomics applications'2002 6,340,595'High throughput screening of gene function using adenoviral libraries for functional genomics applications'2002

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2002–2017Patents assigned to CRUCELL HOLLAND BV (39)· patent assignee history

2002–2020Based in Linschoten, NL· patent location history

2002Based in Linschoren, NL· patent location history

2011–2015Patents assigned to VOGELS RONALD (8)· patent assignee history

2011–2013Patents assigned to HAVENGA MENZO JANS EMCO (6)· patent assignee history

2012–2013Patents assigned to AERAS GLOBAL TB VACCINE FOUND (2)· patent assignee history

2014Based in Eindhoven, NL· patent location history

2016–2020Patents assigned to JANSSEN VACCINES & PREVENTION BV (5)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
CRUCELL HOLLAND BV	39	2002–2017
VOGELS RONALDself	8	2011–2015
HAVENGA MENZO JANS EMCO	6	2011–2013
JANSSEN VACCINES & PREVENTION BV	5	2016–2020
AERAS GLOBAL TB VACCINE FOUND	2	2012–2013

Locations

Location	Patents	Span
Linschoten, NL	45	2002–2020
Eindhoven, NL	1	2014
Linschoren, NL	1	2002